National trends in antiobesity medication use

Archives of Internal Medicine

Volumn 163, Issue 9, 2003, Pages 1046-1050

  Stafford, Randall S ^a   Radley, David C ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; BENZETHONIUM CHLORIDE; BENZPHETAMINE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; IONAMINE; MAZINDOL; METHAMPHETAMINE; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENYLPROPANOLAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; BODY FAT; BODY MASS; CHRONIC DISEASE; COUNSELING; DIET THERAPY; DRUG EFFECT; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RELIABILITY; SAMPLING;

ANTI-OBESITY AGENTS; CROSS-SECTIONAL STUDIES; HUMANS; OBESITY; OBESITY, MORBID; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 0037992871     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.9.1046     Document Type: Article

References (26)

1. National Center for Health Statistics. Prevelence of Overweight and Obesity Among Adults: United States, 1999. Health E-Stats volume. Hyattsville, Md: National Center for Health Statistics; 2000.
2. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39-47.
3. Colditz GA. Economic costs of obesity and inactivity. Med Sci Sports Exerc. 1999; 31:S663-S667.
4. Kordik CP, Reitz AB. Pharmacological treatment of obesity: therapeutic strategies. J Med Chem. 1999;42:181-201.
5. Schmitz MK, Jeffery RW. Public health interventions for the prevention and treatment of obesity. Med Clin North Am. 2000;84:491-512.
6. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report: National Institutes of Health. Obes Res. 1998;6:51S-209S.
7. Rippe JM. The case for medical management of obesity: a call for increased physician involvement. Obes Res. 1998;6:23S-33S.
8. Kristeller JL, Hoerr RA. Physician attitudes toward managing obesity: differences among six specialty groups. Prev Med. 1997;26:542-549.
9. Kushner RF, Weinsier RL. Evaluation of the obese patient: practical considerations, Med Clin North Am. 2000;84:387-399.
10. McArtor RE, Iverson DC, Benken D, Dennis LK. Family practice residents' identification and management of obesity. Int J Obes Relat Metab Disord. 1992;16:335-340.
11. Stafford RS, Farhat JH, Misra B, Schoenfeld DA. National patterns of physician activities related to obesity management. Arch Fam Med. 2000;9:631-638.
12. , Wadden TA, Anderson DA, Foster GD, Bennett A, Steinberg C, Sarwer DB. Obese women's perceptions of their physicians' weight management attitudes and practices. Arch Fam Med. 2000;9:854-860.
13. Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? JAMA. 1999;282:1576-1578.
14. Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry. 1999;60:31-36.
15. Weintraub M. Long-term weight control study. Clin Pharmacol Ther. 1992;51:586-594.
16. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL. Long-term drug treatment of obesity in a private practice setting. Obes Res. 1997;5:578-586.
17. Hensrud DD. Pharmacotherapy for obesity. Med Clin North Am. 2000;84:463-476.
18. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335:609-616.
19. Connolly J, Verni C, Trilling J, Kelso E, Shiesha S. Selections from current literature: pharmacological treatment of obesity. Fam Pract. 1998;15:88-93.
20. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591-602.
21. Terr AI, Bloch DA. Trends in asthma therapy in the United States: 1965-1992. Ann Allergy Asthma Immunol. 1996;76:273-281.
22. Munnangi S, Sonnenberg A. Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Intern Med. 1997;157:1489-1494.
23. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
24. Gay C, Shane-McWhorter L, Williams K, Stone MB. Physician prescribing of anorexigenics for weight loss in Salt Lake County, Utah. Pharmacotherapy. 2000;20:967-973.
25. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among US adults in 1996-1998. Ann Intern Med. 2001;134:282-286.
26. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346:393-403.